Main Article Content
and pregelatinized starch were coated with ethyl cellulose. These ethyl cellulose coated capsules were filled in another capsule and the capsules were coated with a EudragitÂ® S100. The in vitro drug release study was conducted using sequential
dissolution technique at pH 1.2 (two hour), 6.0 (1hr), 7.2 (two hour) and 6.4 (three hour) mimicking different regions of gastrointestinal tract. The optimized batch with two per cent and 6.5% weight gain of ethyl cellulose and EudragitÂ® S100 showed less than eight per cent drug release in stomach and intestinal pH. The remaining 92% drug release was obtained thereafter from the optimized batch within two hours in colonic pH. Scanning electron microscopy study of the optimizedbatch confirmed presence of ibuprofen crystals (rod shape) in the formulation. The infrared spectroscopy study of the
optimized batch indicated stability of ibuprofen during processing of the formulation.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Barbara L, Teresa C, Federica B, Isabella O, Vittorio Z. pH-sensitive
polymeric physical-mixture for possible site-specific delivery of
ibuprofen. Eur J Pharm Biopharm 2003;55:199-202.
Antonin K, Rak R, Beick P, Schenker U, Hastewell J, Fox R, et al. The
absorption of human calcitonin from the transverse colon of man. Int
J Pharm 1996;130:33-9.
Tozaki H, Komoike J, Tada C, Marnyama T, Terabe A, Suzuki T, et al.
Chitosan capsules for colon-specific drug delivery: Improvement of
insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-21.
Van-den M, Kinget R. Oral colon-specific drug delivery: A review. Drug
Rama Prasad Y, Krishnaiah Y, Satyanarayana S. in vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J Control Rel 1998;51:281-7.
Evans D, Pye G, Bramely R, Clark A, Dysoa T. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. An in vivo
investigation into the suitability of pH dependent polymers for colonic
targeting. Int J Pharm 1993;95:193-9.
Davis S, Hardy J, Taylor M, Stockwell A, Whalley D, Wilson C. The in vivo
evaluation of an osmotic device (Osmet) using gamma scintigraphy. J
Pharm Pharmacol 1984;36:740-2.
Marvola M, Aito H, Ponto P, Kanniksoki A, Nykanen S, Kokkonen P.
Gastrointestinal transit and concomitant absorption of verapamil from a
single unit sustained release tablet. Drug Dev Ind Pharm 1987;13:1593-609.
Vyas S, Khar R. Controlled Drug Delivery-Concepts and Advances. New
Delhi: Vallabh Prakashan; 2002. p. 218-56.
Brondsted H, Andersen C, Hovgaard L. Crosslinked dextran-A new
capsule material for colon targeting of drugs. J Control Rel 1998;53:7-13.
Huskisson E. Anti-Rheumatic Drugs. Westport: Praeger Publishers Inc;
Wilson C, Washington N, Greaves J, Kamali F, Rees J, Sempik A, et al.
Bimodal release of ibuprofen in a sustained release formulation:
A scintigraphic and pharmacokinetic open study in healthy
volunteers under different conditions of food intake. Int J Pharm
Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, et al. Effects of
nonselective cyclooxygenase inhibition with low-dose ibuprofen on
tumor growth, angiogenesis, metastasis, and survival in a mouse model
of colorectal cancer. Clin Cancer Res 2005;11:1618-28.
Gohel M, Parikh R, Nagori S, Dabhi M. Design of potential colonic drug
delivery system of mesalamine. Pharm Dev Tech 2008;13:447-56.
Singh BN. Modified-release solid formulations for colonic delivery.
Recent Pat Drug Deliv Formul 2007;1:53-63.
Mariko M, Ayako M, Kozo T, Koichi I, Tsuneji N. Improving insulin
enteral absorption using water-in-oil-in water emulsion. Int J Pharm
Flashner-Barak M, Lerner I, Rosenberger V, Moldavski N. Menthol
solutions of drugs. Patent WO/2004/073686 Sep 2, 2004.
Mckay D, Blumberg J. A review of the bioactivity and potential health
benefits of peppermint tea (Mentha piperita L.). Phytother Res
Nahor H, Chell N, Kamyar H, Carlos K, Osvaldo C, Jenna R, et al. A
multi- cale stochastic drug release model for polymer-coated targeted
s drug delivery systems. J Control Rel 2006;110:314-22.
FranÃ§ois L, Louis C, Roch T. New methods characterizing avalanche
behavior to determine powder flow. Pharm Res 2002;19:887-93.
United States Pharmacopoeia, 2006, Asian edition. United States
Pharmacopoeial Convention Inc: 1842.
Indian Pharmacopoeia. Vol. 1. 1996. p. 736.
Sangalli M, Maroni A, Foppoli A, Zema L, Giordano F, Gazzaniga A.
Different HPMC viscosity grades as coating agents for an oral time
and/or site-controlled delivery system: A study on process parameters
and in vitro performances. Eur J Pharm Sci 2004;22:469-76.
British Pharmacopoeia. Vol. 2. 2001. Appendix XII B.
Pawar A, Paradkar, Kadam S, Mahadik K. Agglomeration of ibuprofen
with talc by novel crystallo-co-agglomeration technique. AAPS
Pharm Sci Tech 2004;5:e55.
Garekani H, Sadeghi F, Badiee A, Mostafa S, Ali R, Rajabi Siahboomi A.
Crystal habit modifications of ibuprofen and their physicomechanical
characteristics. Drug Dev Ind Pharm 2001;27:803-9.
Bunyan J, Shankland N, Sheen D. Solvent effects on the morphology
of ibuprofen. AIChe Symp Ser 1991;87:44-57.
Gordon R, Amin S. Crystallization of ibuprofen. U. S. Patent 44, 76, 248
Oct 9, 1984.
Franz R. Stable, high dose, high bulk density ibuprofen granulations for
tablet and capsule manufacturing. U. S. Patent 46, 09, 675 Sep 2, 1986.
Chen J. Process for enhancing the flow characteristics of ibuprofen. U.
S. Patent 5,191,114 March 2, 1993.
Groenewoud P, Facemire J, Jayanth J. Narcotic composition and method
for making same. Patent WO 2005/037192 April 28, 2005.
Raymond R, Paul S. Handbook of Pharmaceutical Excipients. 4th ed.
London: The Pharmaceutical Press; 1994. p. 373-7, 462-8, 609-11.
Vasanthakumar S, Vijaya R. Immediate release tablets of telmisartan
using superdisintegrant-formulation, evaluation and stability studies.
Chem Pharm Bull 2008;56:575-7.
Inactive Ingredient Guide (Redacted). U.S. Food and Drug Administration,
Center for Drug Evaluation and Research. January, 1996; Available from:
http://www.fda.gov/cder/drug/iig/default.htm. [last accessed on 2006
Meza C, Santos M, RomaÃ±ach R. Quantitation of drug content in a low
dosage formulation by transmission near infrared spectroscopy. AAPS
Pharm Sci tech 2006;7:E29.
Rees J. Mixing of particulate solids to ensure homogeneity of dosage
forms: Need for a critical approach to pharmaceutical process
development. Boll Chim Farm 1977;116:445-62.